European Journal of Dermatology


Real-world effectiveness and tolerability of a cream containing postbiotic Aquaphilus dolomiae extract-G3 in subjects with sensitive facial skin Volume 34, issue 1, January-February 2024


  • Figure 1.

  • Figure 2.

  • Figure 3.

  • Figure 4.


1 Department of Dermatology and Allergology, Ludwig-Maximilian University, D-80337 Munich, Germany, and Department of Dermatology and Allergology, University Hospital Augsburg, D-86179 Augsburg, Germany
2 Department of Dermatology, Hospital del Mar-IMIM, University Pompeu Fabra, 08003 Barcelona, Spain
3 Laboratoires Dermatologiques Avène, Pierre Fabre Dermo-Cosmétique, 81500 Lavaur, France
4 Department of Dermatology and Venereology, Hospital La Paz, 28046 Madrid, Spain
* Reprints: Aline Stennevin


Previous studies indicate that a postbiotic extract from Aquaphilus dolomiae (ADE-G3) improves skin barrier function and relieves neuroinflammation.


Evaluation of an ADE-G3-based soothing cream for managing sensitive facial skin.

Materials & Methods

This real-world, international, pre-post comparative study involved adults with sensitive facial skin who used the study product once or twice daily for two to three months according to usual practice. Subjects reported changes in perceived clinical symptoms using self-administered questionnaires. Physicians assessed changes in xerosis severity, overall product effectiveness and tolerability. User satisfaction and quality of life (QoL) assessments, and subgroup analyses according to the factors triggering sensitive skin were also conducted.


In total, 2,382 subjects with sensitive facial skin (female: 79%; median age: 40 years) were included. An immediate skin soothing effect after the first ADE-G3-based cream application was reported by 93% of subjects, and improvements in symptoms were reported in 94% after a mean of nine days of product use. After several months of use (mean: 71±21 days), xerosis severity and dermatological-related QoL significantly improved in the whole study population and in the subgroups (p<0.001). At the end of the study, 92% of users were satisfied with the product and 95% reported improvements in their overall skin condition. Physicians found the cream to be effective and well tolerated in 92% and 98% of subjects, respectively.


Regular use of the ADE-G3-based cream was shown to be effective in real-world management of sensitive facial skin, regardless of the factors involved in triggering skin sensitivity.

Licence This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License